Nitrofurantoin: Difference between revisions
(Pharm, Contrindications, and Adverse reactions) |
No edit summary |
||
(7 intermediate revisions by 5 users not shown) | |||
Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Cystitis, acute uncomplicated or acute simple:<ref>Nitrofurantoin: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.</ref>=== | |||
*Monohydrate/macrocrystals (Macrobid): 100mg PO q12h | *Monohydrate/macrocrystals (Macrobid): 100mg PO q12h | ||
*Macrocrystals: 50-100mg PO 4 times daily | *Macrocrystals: 50-100mg PO 4 times daily for 5 days | ||
===Cystitis, recurrent, prophylaxis (continuous):<ref>Nitrofurantoin: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.</ref>=== | |||
*Monohydrate/macrocrystals (Macrobid): 100mg PO daily at bedtime | |||
*Macrocrystals: 50-100mg PO daily at bedtime | |||
===Cystitis, postcoital prophylaxis=== | |||
*Monohydrate/macrocrystals (Macrobid): 100mg PO once within 2 hours of sexual intercourse | |||
*Macrocrystals: 50-100mg PO once within 2 hours of sexual intercourse | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Line 21: | Line 30: | ||
*Neonates, pregnant women at term or when delivery imminent | *Neonates, pregnant women at term or when delivery imminent | ||
*Renal failure due to accumulation of metabolites that may cause peripheral neuropathy<ref>Spring PJ, Sharpe DM, Hayes MW. Nitrofurantoin and peripheral neuropathy: A forgotten problem? Med J Aust 2001;174:153-4.</ref> | *Renal failure due to accumulation of metabolites that may cause peripheral neuropathy<ref>Spring PJ, Sharpe DM, Hayes MW. Nitrofurantoin and peripheral neuropathy: A forgotten problem? Med J Aust 2001;174:153-4.</ref> | ||
*CrCL < 60, oliguria, anuria | |||
*Cholestatic jaundice history | *Cholestatic jaundice history | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
Line 65: | Line 72: | ||
*Sialadenitis | *Sialadenitis | ||
*[[Fever]] | *[[Fever]] | ||
*[[ | *[[Pruritus]] | ||
*Urticaria | *Urticaria | ||
*Arthralgia | *Arthralgia | ||
Line 205: | Line 212: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] |
Latest revision as of 22:25, 28 November 2019
General
- Type: Antibiotic
- Dosage Forms: oral
- Common Trade Names: Macrobid
Adult Dosing
Cystitis, acute uncomplicated or acute simple:[1]
- Monohydrate/macrocrystals (Macrobid): 100mg PO q12h
- Macrocrystals: 50-100mg PO 4 times daily for 5 days
Cystitis, recurrent, prophylaxis (continuous):[2]
- Monohydrate/macrocrystals (Macrobid): 100mg PO daily at bedtime
- Macrocrystals: 50-100mg PO daily at bedtime
Cystitis, postcoital prophylaxis
- Monohydrate/macrocrystals (Macrobid): 100mg PO once within 2 hours of sexual intercourse
- Macrocrystals: 50-100mg PO once within 2 hours of sexual intercourse
Pediatric Dosing
- >12yo: same as adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation Risk: Infant risk minimal
- Renal Dosing: Contraindicated if CrCl <60
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Neonates, pregnant women at term or when delivery imminent
- Renal failure due to accumulation of metabolites that may cause peripheral neuropathy[3]
- CrCL < 60, oliguria, anuria
- Cholestatic jaundice history
Adverse Reactions
Serious
- Hemolytic anemia can occur in patients with G6PD deficiency and in infants less than 1 month old
- Hepatic necrosis
- Hepatitis
- Cholestatic jaundice syndrome
- Erythema multiforme/SJS
- Pancreatitis
- Peripheral neuropathy
- Pulmonary hypersensitivity
- Agranulocytosis
- Leukopenia
- Thrombocytopenia
- Pneumonitis
- Pulmonary fibrosis
- Cyanosis
- ECG abnormality
- C. difficle associated diarrhea
- Optic neuritis
- Pseudotumor cerebri
- Psychosis
- Vasculitis
Common
- Nausea
- Headache
- Anorexia
- Abdominal pain
- Diarrhea
- Flatulence
- Asthenia
- Vertigo
- Nystagmus
- Dizziness
- Confusion
- Depression
- Alopecia
- Yellow/brown urine
- Sialadenitis
- Fever
- Pruritus
- Urticaria
- Arthralgia
- Myalgia
- Rigors
Pharmacology
- Half-life: 45-60min
- Metabolism: Hepatic
- Excretion: Urine primarily (30-40% unchanged); Bile
- Mechanism of Action: Inactivates bacterial ribosomal proteins
Antibiotic Sensitivities[4]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Nitrofurantoin: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.
- ↑ Nitrofurantoin: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.
- ↑ Spring PJ, Sharpe DM, Hayes MW. Nitrofurantoin and peripheral neuropathy: A forgotten problem? Med J Aust 2001;174:153-4.
- ↑ Sanford Guide to Antimicrobial Therapy 2014